Rockwell Medical, Inc. · NASDAQ:RMTI
Rockwell Medical — Q4 2025 Earnings Presentation
18 slides from Rockwell Medical's earnings presentation, Mar 26, 2026
Slide 1: Investor Presentation
Investor Presentation March 26, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell’s expectations regarding revenue, profitability, financial position, 2024, 2025 and 2026 guidance, fut
Slide 3: Rockwell Medical At A Glance
Rockwell Medical At A Glance • Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide Business • Leading supplier of liquid bicarbonate hemodialysis concentrates in the U.S. Overview • One of the largest s
Slide 4: Executive Management Team
Executive Management Team Mark Strobeck, PhD Jesse Neri Heather Hunter Tim Chole Megan Timmins President and CEO Chief Financial Officer Chief Operating Officer Chief Commercial Officer Chief Legal Officer ©2026 Rockwell Medical, Inc. 4 ©2026 Rockwell Medical, Inc.
Slide 5: Leading Manufacturer and Supplier of Hemodialysis Concentrates
Leading Manufacturer and Supplier of Hemodialysis Concentrates Hemodialysis is a Necessity for End Stage Kidney Disease Patients • Approximately 490,000 patients in the U.S. require in-center hemodialysis annually(a). • Each patient receives approximately three treatments per week, totaling approxim
Slide 6: U.S. In-Center and Acute Care Hemodialysis Concentrates TAM
U.S. In-Center and Acute Care Hemodialysis Concentrates TAM ~4-6% CAGR driven primarily by increasing number of patients suffering from end-stage kidney disease $450M $560M 2024 2028 SOURCE: CAGR based on “Rockwell Medical: Concentrates Growth Strategy Report”, L.E.K. Consulting LLC (2022) 6 ©2026 R
Slide 7: Rockwell Currently Serves ~300 Customers throughout the U.S. including Top Five Leading Dialysis Providers
Rockwell Currently Serves ~300 Customers throughout the U.S. including Top Five Leading Dialysis Providers Dialysis Providers Hospital Systems Supplier Partners / Distributors 7 ©2026 Rockwell Medical, Inc.
Slide 8: Rockwell Distributes to 30+ Countries Worldwide
Rockwell Distributes to 30+ Countries Worldwide Current Geographic Footprint Current Expansion Opportunities 8 ©2026 Rockwell Medical, Inc.
Slide 9: Financials and Milestones
©) ROCKWELL MEDICAL Financials and Milestones
Slide 10: Fourth Quarter and Full-Year 2025 Financial Results
Fourth Quarter and Full-Year 2025 Financial Results Three Months Ended Twelve Months Ended December 31 December 31 (In Millions, Except Per Share Amounts) 2025 2024 2025 2024 Net Sales $ 18.3 $ 24.7 $ 69.3 $ 101.5 Gross Profit $ 3.9 $ 3.6 $ 11.7 $ 17.5 Gross Margin 21% 15% 17% 17% Net Income (Loss)
Slide 11: Q4'25 Gross Margin represents one of the strongest quarters in Rockwell Medical's history
Q4’25 Gross Margin represents one of the strongest quarters in Rockwell Medical’s history $19.0 21% 18% $14.0 15% 12% $9.0 9% 6% $4.0 3% -$1.0 0% Q1'25 Q2'25 Q3'25 Q4'25 Net Sales Adjusted EBITDA Gross Margin 11 ©2026 Rockwell Medical, Inc.
Slide 12: Profitable on an Adjusted EBITDA Second Year in a Row, Gross Margin Continues to Improve
Profitable on an Adjusted EBITDA Second Year in a Row, Gross Margin Continues to Improve Adjusted EBITDA Gross Margin $5.0 17% 17% $0.4 (in $ millions) -$3.9 10% -$13.8 6% -$28.4 -4% 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 © 2025 Rockwell Medical, Inc. 12 ©2026 Rockwell Medical, Inc.
Slide 13: 2025 Achievements
2025 Achievements ü Achieve sustained profitability for FY’25 on an adjusted EBITDA basis. ü Grew concentrates business by adding new customers. ü Expanded contracts and partnerships with existing customers. ü Continued to optimize our business through improved processes and expanded automated manuf
Slide 14: 3-Year Corporate Strategy (2026-2029)
3-Year Corporate Strategy (2026-2029) Maintain profitable business serving dialysis centers in worldwide • Reliable supply • Consistent quality • Strong customer service • Sustainable margin performance • Shareholder return Build a broader portfolio of renal care products • Integrate into our existi
Slide 15: Long-Term Financial Framework Through 2029
Long-Term Financial Framework Through 2029 Net Sales Profitability Gross Margin $100+ Million $5 Million to $10 million +30% Rockwell Medical believes the Company has a pathway to meaningfully grow its business and generate annual net sales of more than $100 million. Ongoing portfolio diversificatio
Slide 16: Why Invest in Rockwell Medical?
Why Invest in Rockwell Medical? § Large, Recurring Market Opportunity § Profitable, Revenue-Generating Business § Projects to be Cash Flow Positive from Operations in 2026 and beyond § Pursuing Investments in High-Growth Renal Care Opportunities § No Additional Fundraising Required to Achieve Sustai
Slide 17: www.rockwellmed.com
www.rockwellmed.com IR@rockwellmed.com
Slide 18: Reconciliation to GAAP Financial Measures
Reconciliation to GAAP Financial Measures Non-GAAP Financial Measures To supplement the Company’s financial results presented on a U.S. generally accepted accounting principles (“GAAP”) basis, the Company has included information about non-GAAP measures of EBITDA and adjusted EBITDA as useful operat